ArticleTranslational gastroenterology and hepatology2025
Inflammatory sarcopenia, a novel concept in chronic liver disease: insights from magnetic resonance imaging biomarkers.
Article in Translational gastroenterology and hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gut-liver-muscle axis: linking gut microbiota dysbiosis to malnutrition and sarcopenia in liver disease.Frontiers in medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sarcopenia is an important prognostic factor for chronic liver disease (CLD), and systemic inflammation, which contributes to sarcopenia, is also a potent exacerbator of cirrhosis. This study introduces the novel concept of inflammatory sarcopenia (I-SP) and clarifies its clinical profile. Methods: This single-center retrospective study included 762 CLD patients with liver stiffness (LS) measured by magnetic resonance elastography (MRE). I-SP was defined as patients with C-reactive protein (CRP) ≥0.5 mg/dL and low muscle mass assessed by magnetic resonance imaging (MRI), compared with non-sarcopenia (non-SP) and non-I-SP (NI-SP). Prognostic analysis for advanced CLD (ACLD) was conducted using a Cox proportional hazards model, with ACLD defined as LS ≥3 kPa. Results: In CLD, 534, 168, and 60 patients had non-SP, NI-SP, and I-SP, respectively. I-SP patients had a higher complication rate of hepatocellular carcinoma (HCC), which correlated with increased LS and worsening albumin-bilirubin (ALBI) scores (P<0.01 for each). Multivariate logistic regression identified LS (≥3 kPa), ALBI score, alcohol-related liver disease (ALD), and HCC as associated with I-SP (P<0.05 for each). In the follow-up of NI-SP patients (median 36 months), 13% progressed to I-SP and none of the patients had LS <3 kPa. In the ACLD study (n=306), patient survival was stratified into non-SP, NI-SP, and I-SP groups [hazard ratio (HR) reference, 3.4, 15.0, P<0.01 for each]. Multivariate analysis identified ALBI score, HCC, and I-SP as independent prognostic factors (P<0.05 for each). Conclusions: Our study provides a novel perspective on sarcopenia in CLD and advocates a two-step treatment strategy focused on preventing sarcopenia in ACLD and controlling its progression to I-SP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.